By Inteledoc Expert Team | 10 min read | Dr. Naveen Satija, MBBS, FIAGES, DNB (Surgery)
Side effects are one of the first things anyone asks about before starting Wegovy or Mounjaro — and rightfully so. Both are injectable prescription medicines with real side effect profiles that deserve an honest, detailed explanation. But the most important thing to understand upfront is this: the majority of side effects from both medicines are predictable, temporary, and almost entirely preventable with proper medical supervision and correct dose management. This blog gives you the complete picture.
Why Both Medicines Share Most of the Same Side Effects
Wegovy (semaglutide 2.4mg) and Mounjaro (tirzepatide) share the same GLP-1 receptor mechanism. GLP-1 receptors are found in the gut, the brain, the pancreas, and throughout the gastrointestinal system. When you activate them — which is exactly what both medicines do — the body’s digestive rhythm changes: stomach emptying slows, appetite reduces, and the gut-brain signalling system is significantly altered. Most side effects from both medicines are direct consequences of these GI changes, particularly in the early weeks when the body is adjusting to the medicine for the first time.
Because the GLP-1 mechanism is shared, the side effect profiles of Wegovy and Mounjaro are broadly similar. Tirzepatide’s additional GIP mechanism does not appear to meaningfully add to the side effect burden in clinical trials — which is one of the more reassuring findings from the SURMOUNT programme.
✗ MOUNJARO HAS WORSE SIDE EFFECTS THAN WEGOVY BECAUSE IT IS STRONGER
Clinical trial data does not support this. The SURMOUNT-1 trial (tirzepatide) and STEP 1 trial (semaglutide) show comparable rates of GI side effects, with discontinuation rates due to adverse events similarly low in both. Tirzepatide's higher efficacy does not come at the cost of a worse tolerability profile.
The Complete Side Effect Comparison — Wegovy vs Mounjaro
| Side Effect | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Nausea | 44% of patients in trials. Most common in weeks 1–8 during dose escalation. Typically mild-moderate. Resolves for most by week 12. | 44% of patients in SURMOUNT-1. Comparable to semaglutide. Same pattern — peaks during dose increases, resolves with dose stabilisation. |
| Vomiting | 24% in trials. Usually associated with nausea episodes. Rare after week 12. | 22% in SURMOUNT-1. Marginally lower than semaglutide. Same management approach. |
| Diarrhoea | 30% in trials. Usually early in treatment. Self-limiting. | 23% in SURMOUNT-1. Slightly lower rate than semaglutide. |
| Constipation | 24% in trials. Related to slower gastric emptying. Managed with hydration and fibre. | 17% in SURMOUNT-1. Comparable mechanism but slightly lower reported rate. |
| Reduced appetite | Universal — this is the intended mechanism, not a side effect to resist. | Universal — stronger on average due to dual GLP-1/GIP mechanism. |
| Fatigue | 11% in trials. Usually transient in weeks 1–4. | Comparable rate. Typically resolves within first month. |
| Injection site reactions | Mild redness or irritation at injection site. Uncommon. | Similar profile. Rotate injection sites to minimise. |
| Headache | 14% in trials. Often related to dietary changes and reduced caloric intake rather than direct drug effect. | Comparable. Usually resolves within first 4 weeks. |
| Discontinuation rate | 7.0% stopped due to GI side effects in STEP 1. | 4.3% stopped due to GI side effects in SURMOUNT-1. |
The Side Effects That Require Immediate Medical Attention
The following are rare but serious. They require prompt contact with your doctor if they occur:
● Severe abdominal pain — particularly persistent upper abdominal pain radiating to the back. Can indicate pancreatitis — a rare but serious complication. Both medicines carry a small increased risk. Stop the medicine and seek urgent medical review.
● Rapid heartbeat at rest — GLP-1 medicines can cause a modest increase in resting heart rate in some patients. Significant palpitations warrant clinical review.
● Signs of thyroid changes — neck swelling, difficulty swallowing, persistent hoarseness. Both medicines carry a theoretical thyroid C-cell risk (seen in rodent studies; not established in humans but a reason for contraindication in patients with thyroid cancer history).
● Severe hypoglycaemia — particularly in patients also taking sulphonylureas or insulin. GLP-1 medicines improve insulin sensitivity; other diabetes medicines may need dose adjustment.
● Significant vision changes — semaglutide specifically has been associated in some reports with a rare retinal condition called NAION. Report any sudden vision changes promptly.
Why Most Side Effects Are Preventable — The Titration Explanation
The single most important factor in side effect prevention for both Wegovy and Mounjaro is dose titration — starting at the absolute lowest dose and increasing slowly based on individual tolerance. This is not optional caution. It is the clinical mechanism through which the body is given time to adapt to the GLP-1 activation before the dose increases further.
Wegovy titration schedule: 0.25mg weekly for 4 weeks → 0.5mg for 4 weeks → 1.0mg for 4
weeks → 1.7mg for 4 weeks → 2.4mg maintenance. Mounjaro titration schedule: 2.5mg weekly for 4 weeks → 5mg for 4 weeks → then increasing in 2.5mg steps every 4 weeks to a maximum of 15mg based on tolerance.
Providers who rush this schedule — increasing doses faster than the body can adapt — produce unnecessary nausea, vomiting, and the early discontinuation that accounts for the most negative patient experiences reported online. Providers who manage titration correctly produce a very different experience: gradual, manageable adaptation with most patients reporting that initial nausea resolves almost entirely by week 8–12.
✓ HOW INTELEDOC MANAGES SIDE EFFECTS
Every Inteledoc patient receives detailed dose timing guidance, dietary adjustments specifically designed to minimise GI side effects (meal composition, timing relative to injection day, portion sizing), and direct access to their doctor if any concerning symptom arises between consultations. Side effects managed proactively — not reactively. Book your consultation here.
Practical Tips for Minimising Nausea on Both Medicines
1. Eat smaller, lower-fat meals around injection day.
High-fat meals significantly worsen nausea by further slowing gastric emptying that the medicine is already reducing. On injection day and the day after, favour lighter, lower-fat meals — dal, rice, plain curd, steamed vegetables.
2. Eat slowly and stop before you feel completely full.
GLP-1 medicines slow stomach emptying — eating past comfortable fullness on a stomach that empties more slowly than usual produces nausea reliably. Smaller portions, eaten slowly, with deliberate stopping before fullness, reduce this significantly.
3. Stay well hydrated.
Dehydration worsens nausea. Aim for 8–10 glasses of water daily, sipped consistently rather than consumed in large amounts at once.
4. Adjust injection timing.
Many patients find that evening injections result in the peak nausea period (typically 6–12 hours post-injection) occurring during sleep, reducing its practical impact. Your doctor advises on optimal timing based on your individual response.
5. Never increase the dose while experiencing significant nausea.
If the current dose is causing significant GI symptoms, the dose should not increase until symptoms have resolved. Increasing through ongoing nausea produces a compounding effect. Your Inteledoc doctor manages this decision.
6. Jeera water, ginger tea, and small frequent meals.
Traditional Indian remedies for nausea — particularly jeera (cumin) water and fresh ginger tea — are genuinely effective for GLP-1-related nausea and compatible with both medicines.
The Side Effect That Surprises Most Patients — Muscle Loss
Not listed on the package insert but critically important: both Wegovy and Mounjaro suppress appetite so effectively that patients often eat far too little protein. Insufficient protein during a caloric deficit causes the body to break down muscle tissue alongside fat. Losing muscle reduces metabolic rate and worsens body composition — even if the scale is moving in the right direction.
This is not a direct pharmacological side effect of either medicine. It is a consequence of unsupervised use without nutritional guidance. Inteledoc’s programmes establish specific protein targets from day one (1.2–1.6g per kg body weight) and provide practical guidance for meeting them within Indian dietary culture — preventing muscle loss before it begins.
💊 INTELEDOC PROGRAMME PLANS
3 Months Plan
GLP-1 Plan
₹4,500
Metabolic Plus
₹9,000
6 Months Plan
GLP-1 Plan
₹7,500
Metabolic Plus
₹15,000
12 Months Plan
GLP-1 Plan
₹12,000
Metabolic Plus
₹24,000
Frequently Asked Questions
Clinical trial data shows comparable side effect profiles. Mounjaro’s SURMOUNT-1 trial actually
showed marginally lower rates of nausea, vomiting, and diarrhoea than Wegovy’s STEP 1 trial —
and a lower discontinuation rate due to GI side effects (4.3% vs 7.0%). Neither medicine is clearly
worse in tolerability.
For most patients, nausea peaks in the first 4–8 weeks during dose escalation and resolves substantially by weeks 10–12 as the body adapts. Patients on properly managed titration schedules typically report very manageable nausea levels after the first month.
Your doctor can prescribe short-term anti-nausea medication if needed during early dose escalation. Metoclopramide and ondansetron have been used in this context. Do not self prescribe — always check with your Inteledoc doctor.
Hair loss (telogen effluvium) is not a direct pharmacological effect of either medicine. It can occur as a consequence of rapid weight loss — any approach producing rapid weight loss can trigger temporary hair shedding. Adequate protein intake and a managed rate of weight loss (both emphasised in Inteledoc’s programme) significantly reduce this risk.
Alcohol worsens nausea — the most common early side effect — and adds empty calories working against weight loss goals. Moderate consumption is not strictly contraindicated but is generally discouraged during the early treatment phase. Your doctor will give specific guidance.
Both medicines can cause a modest increase in resting heart rate in some patients — typically 2– 4 beats per minute on average. For most patients this is clinically insignificant. Patients with preexisting cardiac conditions are assessed specifically at the pre-treatment evaluation.
Both occur. Diarrhoea is more common early in treatment (the gut adjusting to altered motility). Constipation becomes more common as treatment continues and gastric emptying slows. Both are managed through dietary adjustments — hydration, fibre, and meal timing.
Contact your Inteledoc doctor. Vomiting after injection does not affect medicine absorption (it is already in the subcutaneous tissue), but persistent vomiting warrants clinical review and possible dose adjustment.
Pancreatitis is a rare but listed risk with both medicines. History of pancreatitis is a contraindication — identified in pre-treatment screening. Report any severe, persistent upper abdominal pain immediately.
Through careful gradual dose titration, specific dietary guidance for injection day and the days following, protein targets that prevent muscle loss, regular doctor check-ins to catch and address any emerging side effects, and direct doctor access between appointments for urgent concerns.
Starting Wegovy or Mounjaro? Get proper medical supervision from day one.
Inteledoc — India's first metabolonomics-based weight loss programme. Doctor supervised, online across India & in-person in Gurugram.
Book a consultation